Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F.
Michel LL, et al. Among authors: schneeweiss a.
Breast Cancer Res Treat. 2019 Sep;177(2):437-446. doi: 10.1007/s10549-019-05314-9. Epub 2019 Jun 24.
Breast Cancer Res Treat. 2019.
PMID: 31236813